To investigate the prevalence, probable mechanisms and serotype correlation of colistin resistance in clinical isolates of from patients in China, isolates were collected from fecal and blood samples of patients. In this study, 42.8% (136/318) clinical isolated were resistant to colistin. MIC distribution for colistin at serotype level among the two most prevalent serotypes originating from humans in China indicated that Enteritidis (83.9% resistance, 125/149) were significantly less susceptible than Typhimurium (15.3% resistance, 9/59, < 0.01). genes and mutations in PmrAB confer little for rate of colistin resistant isolated from human patients. Phylogenetic tree based on core-genome single nucleotide polymorphisms (SNPs) was separately by the serotypes and implied a diffused distribution of MICs in the same serotype isolates. Relatvie expression levels of colistin resistant related genes were significantly higher in non- colistin resistant Typhimurium than in colistin sensitive Typhimurium, but no discernable differences between colistin resistant and sensitive Enteritidis, indicating a different mechanism between colistin resistant Typhimurium and Enteritidis. In conclusion, colistin susceptibility and colistin resistant mechanism of clinical isolated were closely associated with specific serotypes, at least in the two most prevalent serotype Enteritidis and Typhimurium. We suggest clinical microbiology laboratory interpreting colistin MIC results in the serotype level.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7775366 | PMC |
http://dx.doi.org/10.3389/fmicb.2020.592146 | DOI Listing |
Rev Argent Microbiol
January 2025
Department of Microbiology, School of Medicine and PhD Program in Clinical Medicine and Public Health, University of Granada & Ibs, Granada, Spain; Department of Microbiology, Hospital Virgen de las Nieves, Institute for Biosanitary Research-Ibs, Granada, Spain.
Carbapenemase-producing Enterobacterales (CPE) have increased in the last decade. In low-income countries, colistin is considered a last resort antimicrobial to treat CPE infections, whose most worrisome mechanism of resistance is MCR-1 production. This study aims to understand the epidemiology of colistin resistance in CPE in the region, through the surveillance of the mcr-1 gene in CPE isolates in Ecuador.
View Article and Find Full Text PDFIndian J Nephrol
July 2024
Department of Nephrology, M S Ramaiah Medical College, Bangalore, India.
Background: Carbapenem-resistant urinary tract infections (CR-UTIs) are a major global health threat. Many factors contribute to the increasing incidence of CR-UTI. Owing to the limited availability of treatment options, CR-UTIs are highly challenging to treat.
View Article and Find Full Text PDFMicrobiol Resour Announc
January 2025
Center for Bioscience and Biotechnology, University of Science, Ho Chi Minh, Vietnam.
Colistin resistance threatens global health as it compromises the effectiveness of a last-resort antibiotic. We present the complete genome sequence of ST462, which carries the gene, isolated from a pediatric diarrhea case in southern Vietnam. The 5,049,362 bp genome contains 24 resistance genes distributed across 107 contigs.
View Article and Find Full Text PDFUnlabelled: is a high-priority organism for the development of new antibacterial treatments. We found that the antimalarial medication mefloquine (MFQ) permeabilized the bacterial cell membrane of , decreased membrane fluidity, and caused physical injury to the membrane. MFQ also maintained activity across different pH conditions (PH range 5-8).
View Article and Find Full Text PDFBackground And Aims: Urinary tract infections (UTIs) are a prevalent bacterial infection that has substantial implications for healthcare on a global scale. () is a gram-negative rod responsible for most UTI cases. ESBL-producing is widely recognized as a significant contributor to antibiotic resistance.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!